Last reviewed · How we verify

non-RAS inhibitor antihypertensive therapy

Mario Negri Institute for Pharmacological Research · Phase 3 active Small molecule

non-RAS inhibitor antihypertensive therapy is a Non-RAS inhibitor antihypertensive Small molecule drug developed by Mario Negri Institute for Pharmacological Research. It is currently in Phase 3 development for Hypertension.

Non-RAS inhibitor antihypertensive therapy works by blocking the action of certain natural chemicals in the body that cause blood vessels to constrict, leading to a decrease in blood pressure.

Non-RAS inhibitor antihypertensive therapy works by blocking the action of certain natural chemicals in the body that cause blood vessels to constrict, leading to a decrease in blood pressure. Used for Hypertension.

At a glance

Generic namenon-RAS inhibitor antihypertensive therapy
SponsorMario Negri Institute for Pharmacological Research
Drug classNon-RAS inhibitor antihypertensive
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Non-RAS inhibitors are a class of antihypertensive drugs that target various pathways to lower blood pressure. They do not inhibit the renin-angiotensin-aldosterone system (RAS), which is targeted by other antihypertensive drugs. Instead, they work through different mechanisms to relax blood vessels and improve blood flow.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about non-RAS inhibitor antihypertensive therapy

What is non-RAS inhibitor antihypertensive therapy?

non-RAS inhibitor antihypertensive therapy is a Non-RAS inhibitor antihypertensive drug developed by Mario Negri Institute for Pharmacological Research, indicated for Hypertension.

How does non-RAS inhibitor antihypertensive therapy work?

Non-RAS inhibitor antihypertensive therapy works by blocking the action of certain natural chemicals in the body that cause blood vessels to constrict, leading to a decrease in blood pressure.

What is non-RAS inhibitor antihypertensive therapy used for?

non-RAS inhibitor antihypertensive therapy is indicated for Hypertension.

Who makes non-RAS inhibitor antihypertensive therapy?

non-RAS inhibitor antihypertensive therapy is developed by Mario Negri Institute for Pharmacological Research (see full Mario Negri Institute for Pharmacological Research pipeline at /company/mario-negri-institute-for-pharmacological-research).

What drug class is non-RAS inhibitor antihypertensive therapy in?

non-RAS inhibitor antihypertensive therapy belongs to the Non-RAS inhibitor antihypertensive class. See all Non-RAS inhibitor antihypertensive drugs at /class/non-ras-inhibitor-antihypertensive.

What development phase is non-RAS inhibitor antihypertensive therapy in?

non-RAS inhibitor antihypertensive therapy is in Phase 3.

What are the side effects of non-RAS inhibitor antihypertensive therapy?

Common side effects of non-RAS inhibitor antihypertensive therapy include Headache, Dizziness, Fatigue.

Related